MX2019002097A - Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. - Google Patents

Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer.

Info

Publication number
MX2019002097A
MX2019002097A MX2019002097A MX2019002097A MX2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
receptor antagonists
androgen receptor
subject
Prior art date
Application number
MX2019002097A
Other languages
English (en)
Inventor
C Bignan Gilles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019002097A publication Critical patent/MX2019002097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos, composiciones y metodos para tratar y/o mejorar enfermedades, sindromes, trastornos o afecciones asociadas con receptores mutantes del AR vinculados al cancer de prostata resistente a la castracion, en un sujeto, que incluye un mamífero y/o humano, que lo necesita, que ha demostrado resistencia a antagonistas del AR de primera o segunda generacion, que comprende, consiste y/o que consiste esencialmente en administrar a un sujeto que lo necesita una cantidad terapeuticamente eficaz de un compuesto de la Formula (I). (ver fórmula) en donde R1, G, R10 y R11 se definen en la presente descripcion.
MX2019002097A 2016-08-22 2017-08-22 Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. MX2019002097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019002097A true MX2019002097A (es) 2019-05-15

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002097A MX2019002097A (es) 2016-08-22 2017-08-22 Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20190209539A1 (es)
EP (1) EP3500259A1 (es)
JP (1) JP2019528290A (es)
KR (1) KR20190040030A (es)
CN (1) CN109640986A (es)
AU (1) AU2017316756A1 (es)
BR (1) BR112019003406A2 (es)
CA (1) CA3034449A1 (es)
MA (1) MA45992A (es)
MX (1) MX2019002097A (es)
RU (1) RU2019108092A (es)
WO (1) WO2018037342A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018314980B2 (en) * 2017-08-07 2022-05-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Diarylthiohydantoin compound as androgen receptor antagonist
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3124481T (pt) * 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
CA2889756C (en) * 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators

Also Published As

Publication number Publication date
RU2019108092A3 (es) 2020-11-30
CA3034449A1 (en) 2018-03-01
AU2017316756A1 (en) 2019-02-21
CN109640986A (zh) 2019-04-16
KR20190040030A (ko) 2019-04-16
RU2019108092A (ru) 2020-09-22
US20190209539A1 (en) 2019-07-11
JP2019528290A (ja) 2019-10-10
BR112019003406A2 (pt) 2019-05-21
MA45992A (fr) 2019-06-26
WO2018037342A1 (en) 2018-03-01
EP3500259A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
PH12013501341A1 (en) Morphinan compounds
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
IN2015KN00414A (es)
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
MX2015012006A (es) Inhibidores de bromodominio tetraciclicos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
NZ726366A (en) Syk inhibitors
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
UA114944C2 (uk) Піридинільні і конденсовані піридинільні похідні триазолону
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MY199091A (en) Therapeutic compounds
PH12016502352A1 (en) Pharmaceutical composition
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2015012741A (es) Palbociclib deuterado.
MX2021002556A (es) Tratamiento del dolor postquirurgico.
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
NZ734635A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat